Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 333 versus Vosoritide in Children with Achondroplasia
jRCT2011260022Phase 3Recruiting
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised trial of BMN 333 in achondroplasia (ACH) (2 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoints: Phase 2: Predicted Annualized Growth Velocity at Week 52 and Phase 3: Annualized Growth Velocity at Week 52. Started Jul 2026; status: recruiting.
02
Drugs
BMN 333
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on jRCT2011260022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260022.